



ASX / Media Release  
23 June 2021

## Notice of Upcoming Release of Securities from Escrow

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatide) for neurological conditions relating to raised intracranial pressure, today advises that in accordance with ASX Listing Rule 3.10A, 21,069,220 shares subject to ASX escrow are to be released from escrow on 7 July 2021, being 24 months since the date of official quotation of Invex securities on ASX.

- ENDS -

*This release dated 23 June 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.*

---

### For more information, please contact:

#### Company/Investors

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

#### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter [@InvexThera\\_ASX](https://twitter.com/InvexThera_ASX)

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).